AETHLON MEDICAL INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that AETHLON MEDICAL INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Mar 31, 2024 | $0 | Jun 27, 2024 |
| FY2024 | Mar 31, 2023 | $574.2K | Jun 27, 2024 |
| FY2023 | Mar 31, 2022 | $294.2K | Jun 28, 2023 |
| FY2022 | Mar 31, 2021 | $659.1K | Jun 28, 2022 |
| FY2021 | Mar 31, 2020 | $650.2K | Jun 24, 2021 |
| FY2020 | Mar 31, 2019 | $229.6K | Jun 25, 2020 |
| FY2018 | Mar 31, 2018 | $149.6K | Jul 1, 2019 |
| FY2018 | Mar 31, 2017 | $392.1K | Jun 8, 2018 |
| FY2017 | Mar 31, 2016 | $886.6K | Jun 28, 2017 |
| FY2016 | Mar 31, 2015 | $762.4K | Jun 29, 2016 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Mar 31, 2024 | $0 | Jun 27, 2024 |
| FY2024 | Mar 31, 2023 | $574.2K | Jun 27, 2024 |
| FY2023 | Mar 31, 2022 | $294.2K | Jun 28, 2023 |
| FY2022 | Mar 31, 2021 | $659.1K | Jun 28, 2022 |
| FY2021 | Mar 31, 2020 | $650.2K | Jun 24, 2021 |
| FY2020 | Mar 31, 2019 | $229.6K | Jun 25, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($13.39M) | Jun 26, 2025 |
| FY2025 | Mar 31, 2024 | ($12.21M) | Jun 26, 2025 |
| FY2024 | Mar 31, 2023 | ($12.03M) | Jun 27, 2024 |
| FY2023 | Mar 31, 2022 | ($10.42M) | Jun 28, 2023 |
| FY2022 | Mar 31, 2021 | ($7.89M) | Jun 28, 2022 |
| FY2021 | Mar 31, 2020 | ($6.37M) | Jun 24, 2021 |
| FY2020 | Mar 31, 2019 | ($6.19M) | Jun 25, 2020 |
| FY2018 | Mar 31, 2018 | ($5.68M) | Jul 1, 2019 |
| FY2018 | Mar 31, 2017 | ($7.28M) | Jun 8, 2018 |
| FY2017 | Mar 31, 2016 | ($4.87M) | Jun 28, 2017 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($9.34M) | Jun 26, 2025 |
| FY2025 | Mar 31, 2024 | ($12.64M) | Jun 26, 2025 |
| FY2024 | Mar 31, 2023 | ($11.90M) | Jun 27, 2024 |
| FY2023 | Mar 31, 2022 | ($10.42M) | Jun 28, 2023 |
| FY2022 | Mar 31, 2021 | ($7.89M) | Jun 28, 2022 |
| FY2021 | Mar 31, 2020 | ($5.93M) | Jun 24, 2021 |
| FY2020 | Mar 31, 2019 | ($6.00M) | Jun 25, 2020 |
| FY2018 | Mar 31, 2018 | ($4.83M) | Jul 1, 2019 |
| FY2018 | Mar 31, 2017 | ($6.10M) | Jun 8, 2018 |
| FY2017 | Mar 31, 2016 | ($4.38M) | Jun 28, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $2.21M | Jun 26, 2025 |
| FY2025 | Mar 31, 2024 | $2.52M | Jun 26, 2025 |
| FY2024 | Mar 31, 2023 | $2.75M | Jun 27, 2024 |
| FY2023 | Mar 31, 2022 | $2.34M | Jun 28, 2023 |
| FY2022 | Mar 31, 2021 | $2.07M | Jun 28, 2022 |
| FY2021 | Mar 31, 2020 | $927.0K | Jun 24, 2021 |
| FY2020 | Mar 31, 2019 | $896.0K | Jun 25, 2020 |
| FY2018 | Mar 31, 2018 | $586.0K | Jul 1, 2019 |
| FY2018 | Mar 31, 2017 | $673.0K | Jun 8, 2018 |
| FY2017 | Mar 31, 2016 | $782.0K | Jun 28, 2017 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($7.65M) | Jun 26, 2025 |
| FY2025 | Mar 31, 2024 | ($10.13M) | Jun 26, 2025 |
| FY2024 | Mar 31, 2023 | ($10.51M) | Jun 27, 2024 |
| FY2023 | Mar 31, 2022 | ($9.77M) | Jun 28, 2023 |
| FY2022 | Mar 31, 2021 | ($6.76M) | Jun 28, 2022 |
| FY2021 | Mar 31, 2020 | ($5.20M) | Jun 24, 2021 |
| FY2020 | Mar 31, 2019 | ($4.29M) | Jun 25, 2020 |
| FY2018 | Mar 31, 2018 | ($3.91M) | Jul 1, 2019 |
| FY2018 | Mar 31, 2017 | ($3.51M) | Jun 8, 2018 |
| FY2017 | Mar 31, 2016 | ($4.33M) | Jun 28, 2017 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $0 | Jun 26, 2025 |
| FY2025 | Mar 31, 2024 | $250.9K | Jun 26, 2025 |
| FY2024 | Mar 31, 2023 | $943.1K | Jun 27, 2024 |
| FY2023 | Mar 31, 2022 | $349.2K | Jun 28, 2023 |
| FY2022 | Mar 31, 2021 | $59.9K | Jun 28, 2022 |
| FY2021 | Mar 31, 2020 | $151.7K | Jun 24, 2021 |
| FY2020 | Mar 31, 2019 | $0 | Jun 25, 2020 |
| FY2018 | Mar 31, 2018 | $24.8K | Jul 1, 2019 |
| FY2018 | Mar 31, 2017 | $16.4K | Jun 8, 2018 |
| FY2017 | Mar 31, 2016 | $9.3K | Jun 28, 2017 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $7.36M | Jun 26, 2025 |
| FY2025 | Mar 31, 2024 | $8.25M | Jun 26, 2025 |
| FY2024 | Mar 31, 2023 | $17.51M | Jun 27, 2024 |
| FY2023 | Mar 31, 2022 | $19.42M | Jun 28, 2023 |
| FY2022 | Mar 31, 2021 | $10.67M | Jun 28, 2022 |
| FY2021 | Mar 31, 2020 | $10.39M | Jun 24, 2021 |
| FY2020 | Mar 31, 2019 | $4.12M | Jun 25, 2020 |
| FY2018 | Mar 31, 2018 | $7.35M | Jul 1, 2019 |
| FY2018 | Mar 31, 2017 | $1.73M | Jun 8, 2018 |
| FY2017 | Mar 31, 2016 | $2.53M | Jun 28, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $2.24M | Jun 26, 2025 |
| FY2025 | Mar 31, 2024 | $2.48M | Jun 26, 2025 |
| FY2024 | Mar 31, 2023 | $2.44M | Jun 27, 2024 |
| FY2023 | Mar 31, 2022 | $2.43M | Jun 28, 2023 |
| FY2022 | Mar 31, 2021 | $1.38M | Jun 28, 2022 |
| FY2021 | Mar 31, 2020 | $1.11M | Jun 24, 2021 |
| FY2020 | Mar 31, 2019 | $1.82M | Jun 25, 2020 |
| FY2018 | Mar 31, 2018 | $1.32M | Jul 1, 2019 |
| FY2018 | Mar 31, 2017 | $1.13M | Jun 8, 2018 |
| FY2017 | Mar 31, 2016 | $1.03M | Jun 28, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $5.12M | Jun 26, 2025 |
| FY2025 | Mar 31, 2024 | $5.77M | Jun 26, 2025 |
| FY2025 | Mar 31, 2023 | $15.06M | Jun 26, 2025 |
| FY2024 | Mar 31, 2022 | $16.99M | Jun 27, 2024 |
| FY2022 | Mar 31, 2021 | $9.43M | Jun 28, 2022 |
| FY2021 | Mar 31, 2020 | $9.41M | Jun 24, 2021 |
| FY2020 | Mar 31, 2019 | $2.43M | Jun 25, 2020 |
| FY2018 | Mar 31, 2018 | $6.13M | Jul 1, 2019 |
| FY2018 | Mar 31, 2017 | $676.4K | Jun 8, 2018 |
| FY2017 | Mar 31, 2016 | $1.55M | Jun 28, 2017 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($167.95M) | Jun 26, 2025 |
| FY2025 | Mar 31, 2024 | ($154.57M) | Jun 26, 2025 |
| FY2024 | Mar 31, 2023 | ($142.36M) | Jun 27, 2024 |
| FY2023 | Mar 31, 2022 | ($130.33M) | Jun 28, 2023 |
| FY2022 | Mar 31, 2021 | ($119.91M) | Jun 28, 2022 |
| FY2021 | Mar 31, 2020 | ($112.03M) | Jun 24, 2021 |
| FY2020 | Mar 31, 2019 | ($105.65M) | Jun 25, 2020 |
| FY2018 | Mar 31, 2018 | ($99.46M) | Jul 1, 2019 |
| FY2018 | Mar 31, 2017 | ($93.78M) | Jun 8, 2018 |
| FY2017 | Mar 31, 2016 | ($86.50M) | Jun 28, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $5.50M | Jun 26, 2025 |
| FY2025 | Mar 31, 2024 | $5.44M | Jun 26, 2025 |
| FY2024 | Mar 31, 2023 | $14.53M | Jun 27, 2024 |
| FY2023 | Mar 31, 2022 | $17.07M | Jun 28, 2023 |
| FY2021 | Mar 31, 2021 | $9.86M | Jun 24, 2021 |
| FY2021 | Mar 31, 2020 | $9.60M | Jun 24, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | (8) | Jun 26, 2025 |
| FY2025 | Mar 31, 2024 | (38) | Jun 26, 2025 |
| FY2024 | Mar 31, 2023 | (5) | Jun 27, 2024 |
| FY2023 | Mar 31, 2022 | 0 | Jun 28, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | (8) | Jun 26, 2025 |
| FY2025 | Mar 31, 2024 | (38) | Jun 26, 2025 |
| FY2024 | Mar 31, 2023 | (5) | Jun 27, 2024 |
| FY2023 | Mar 31, 2022 | 0 | Jun 28, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 2.01M | Jun 26, 2025 |
| FY2025 | Mar 31, 2024 | 328,728 | Jun 26, 2025 |
| FY2024 | Mar 31, 2023 | 2.30M | Jun 27, 2024 |
| FY2023 | Mar 31, 2022 | 15.42M | Jun 28, 2023 |
| FY2022 | Mar 31, 2021 | 12.15M | Jun 28, 2022 |
| FY2021 | Mar 31, 2020 | 9.37M | Jun 24, 2021 |
| FY2020 | Mar 31, 2019 | 1.27M | Jun 25, 2020 |
| FY2018 | Mar 31, 2018 | 17.74M | Jul 1, 2019 |
| FY2018 | Mar 31, 2017 | 8.80M | Jun 8, 2018 |
| FY2017 | Mar 31, 2016 | 7.62M | Jun 28, 2017 |